
The Molecular Basis of Small Vessel
Constriction in Endothelin-1 Models and
Peripheral Arterial Disease

Kanchani Rajopadhyaya

Discipline of Physiology, School of Medical Science

The University of Adelaide

May 2013

A thesis submitted for the degree of Doctor of Philosophy

Table of contents

Thesis declaration	8
Acknowledgements	9
List of figures and tables	10
List of common abbreviations	12
Thesis abstract	14
A. Literature Review	16
A1. Peripheral artery disease	17
A1.1. Clinical characteristics	17
A1.2. Diagnosing PAD	18
A1.3. The prevalence of PAD	20
A1.4. Risk factors	21
A1.5. Treating PAD	23
A1.6. Large vs small vessel disease in the peripheral circulation	26
A2. The pathophysiology of PAD	29
A2.1. Atherosclerosis	29
A2.2. Thrombosis	30
A2.3. Vasospasm and increased vascular tone	31
A3. The endothelium	35
A3.1. The role of the endothelium in regulating vascular tone	35
A3.2. Endothelial dysfunction	36
A3.3. Nitric oxide	37
A3.4. Endothelial nitric oxide synthase	38
A3.5. Regulation of eNOS activity by Ca ²⁺	40
A3.6. Regulation of eNOS activity by Ser1177 phosphorylation	41
A3.7. Non-NO endothelial-derived vasodilators	43
A4. Molecular mechanism underlying vascular smooth muscle tone	46
A4.1. The contractile apparatus	46
A4.2. Regulation of contraction via myosin light chain kinase	47
A4.3. Regulation of Ca ²⁺ entry	47

A4.4. Regulation of Ca ²⁺ sensitisation via myosin light chain phosphatase	51
A4.5. PKC/CPI-17-mediated Ca ²⁺ sensitisation	52
A4.6. RhoA/ROK-mediated Ca ²⁺ sensitisation	54
A5. The physiological role and molecular basis of important vasoconstrictors	58
A5.1. α_1 -adrenergic receptor activation	58
A5.2. Thromboxane A ₂	61
A5.3. Endothelin-1	63
A5.4. Serotonin	65
A6. Thesis aims	69
B. General Methods	70
B1. Materials	71
B1.1 Functional myography	71
B1.2. Mini-osmotic pump and jugular vein cannulation	71
B1.3. Sodium dodecyl sulphate polyacrylamide gel electrophoresis	71
B1.4. Western blot analysis	72
B2. Functional vascular myography	73
B2.1. Background	73
B2.2. Animal tissue preparation	73
B2.3. Human tissue preparation	75
B2.4. Tissue integrity	75
B2.5. Resting tension	76
B2.6. Endothelial integrity	76
B2.7. Experimental protocol – single dose	77
B2.8. Experimental protocol – dose response	78
B2.9. Snap-freezing and tissue storage	78
B2.10. Data analysis	78
B3. Chronic endothelin-1 infusion model	80
B3.1. Background	80
B3.2. Preparation of mini-osmotic pumps	81
B3.3. Jugular vein cannulation and mini-pump implantation	82
B4. SDS-PAGE	84
B4.1. Background	84

B4.2. Sample preparation	84
B4.3. SDS-polyacrylamide gel preparation	85
B4.4. SDS-PAGE run	87
B4.5. Standardising volume loading	87
B4.6. Protein transfer to nitrocellulose membrane	88
B5. Western Blot Analysis	89
B5.1. Background	89
B5.2. Blocking	89
B5.3. Primary antibody	89
B5.4. Biotin-conjugated secondary IgG	90
B5.5. Streptavidin-conjugated 800nm fluorochrome	90
B5.6. Re-probe with monoclonal anti-MYPT and anti-eNOS	91
B5.7. Incubation with HRP-conjugated secondary IgG	91
B5.8. ECL detection	91
B5.9. Data analysis	92
C. PKC inhibition attenuated sustained endothelin-1-mediated vasoconstriction while ROK inhibition attenuated initial and sustained endothelin-1-mediated vasoconstriction in large and small arteries	93
C1. Introduction	94
C2. Methods	97
C2.1. Materials	97
C2.2. Functional vascular myography	97
C2.3. Data analysis	98
C3. Results	99
C3.1. Inhibition of PKC and ROK prior to ET-1 stimulation attenuated the development and maintenance of vasoconstriction in rat caudal artery	100
C3.2. Inhibition of PKC and ROK prior to ET-1 stimulation attenuated the development and maintenance of vasoconstriction in rat mesenteric arteries	104
C3.3. During the sustained phase of ET-1-mediated contraction subsequent inhibition of PKC and ROK attenuates vasoconstriction in rat caudal arteries	108
C4. Discussion	110

D. Chronic endothelin-1 infusion attenuated thromboxane A₂-mediated vasoconstriction in second order rat mesenteric arteries	117
D1. Introduction	118
D2. Methods	121
D2.1. Materials	121
D2.2. Preparation of mini-osmotic pumps and jugular vein cannulation	122
D2.3. Functional vascular myography	124
D2.4. SDS-PAGE and western blot analysis of eNOS and myosin phosphatase	125
D2.5. Data analysis	127
D3. Results	128
D3.1. Chronic exposure to elevated ET-1 decreased the sensitivity and maximum contractile response to exogenously applied thromboxane A ₂ mimetic, U46619	129
D3.2. The contractile response to exogenously applied ET-1 is similar in rats chronically exposed to elevated ET-1	131
D3.3. The contractile response to the exogenously applied α_1 -adrenergic receptor agonist, phenylephrine and serotonin are similar in rats chronically exposed to elevated ET-1	133
D3.4. Chronic exposure to elevated ET-1 does not alter the contractile response to KCl-mediated depolarisation	136
D3.5. The abundance and activation state of eNOS is similar in rats chronically exposed to ET-1	138
D3.6. The abundance and activation state of myosin phosphatase is not significantly different in rats chronically exposed to ET-1	140
D4. Discussion	142
E. Subcutaneous microvessels from patients suffering from peripheral artery disease exhibit enhanced serotonin and α_1-adrenergic receptor mediated vasoconstriction	148
E1. Introduction	149
E2. Methods	153
E2.1. Materials	153
E2.2. Patient recruitment and tissue collection	154

E2.3. Functional vascular response	155
E2.4. SDS-Page and western blot analysis of eNOS, myosin phosphatase and 5HT _{2A}	156
E2.5. Data analysis	157
E3. Results	159
E3.1. PAD and age-matched non-PAD patients had similar responses to KCl-mediated vasoconstriction	163
E3.2. The maximum vasoconstrictor response to serotonin receptor activation is increased in patients with PAD compared to age-matched patients asymptomatic for PAD	165
E3.3. The maximum vasoconstrictor response to α_1 -adrenergic receptor activation is increased in patients with PAD compared to age-matched patients asymptomatic for PAD	167
E3.4. Patients with and without PAD have similar sensitivity and maximum vasoconstrictor responses to thromboxane A ₂ receptor activation	169
E3.5. Patients with and without PAD have similar sensitivity and maximum vasoconstrictor responses to ET-1 receptor activation	171
E3.6. Patients with and without symptomatic PAD have similar abundance and Ser1177 phosphorylation state of eNOS in subcutaneous arteries	173
E3.7. Subcutaneous arteries from patients with and without PAD have similar abundance and Thr855 MYPT-dependent activation state of myosin phosphatase	177
E3.8. Subcutaneous arteries from patients suffering with PAD have increased abundance of total 5HT _{2A} receptors compared to patients asymptomatic for PAD	179
E4. Discussion	181
F. General Discussion	192
F1. Thesis discussion	193
F1.1. Thesis premise	193
F1.2. Summary of results	194
F1.3. Is there a need to consider alternative to Ca ²⁺ channel and multiple G-protein coupled receptor blockade therapy?	196
F1.4. The influence of elevated ET-1 in vascular disease	198
F1.5. The pathophysiology of vascular reactivity in patients with PAD	200

F1.6. Conclusions	202
References	204

Thesis Declaration

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Signed,

Kanchani Rajopadhyaya

Acknowledgements

I thank my primary supervisor Dr. David Wilson for his invaluable support and guidance. I owe much of this thesis and my growth as an investigator to his unique ability to encourage and motivate. Above all, I thank him for his patience through this immense learning experience. His commitment to teaching and his passion for research is inspirational and I am truly grateful for his belief in me.

I extend my sincere gratitude to my supervisors Prof. John Beltrame and Prof. Robert Fitridge for their guidance and clinical perspective throughout my PhD career. Together my supervisors hold an unfathomable wealth of knowledge and I treasured their willingness to share this with me.

To my mother Laxmi Sharma, my brother Brajesh Rajopadhyaya, my partner Kemuel Kitto and my close friends, particularly Janine Van Heer and Hien Le: I am grateful for your love and encouragement at home. I am especially thankful for your understanding during the challenging periods and for sharing with me the joys of achievement and success.

To my colleagues and friends: Jessica Maddern, Scott Copley, Timothy Spencer, Joanne Eng, Yann Chan, Amenah Jaghoori, Rachel Dreyer, Rachel Jakobczak, Lauren Rimmer and Benjamin Reddi: I thank you for creating such an enjoyable and supportive work environment. I was grateful for your camaraderie through the many highs and lows and I especially thank you for the countless laughs and crazy antics in the lab. I wish you all the very best in your future endeavours.

List of figures and tables

Figure A1.	Molecular basis of eNOS-mediated nitric oxide generation in the endothelium.	45
Figure A2.	Molecular mechanisms involved in vascular smooth muscle contraction.	57
Figure C1.	In rat caudal artery, inhibition of ROK but not PKC prior to ET-1 stimulation attenuated the initiation of vasoconstriction.	102
Figure C2.	In rat caudal artery inhibition of ROK but not PKC prior to ET-1 stimulation attenuated the sustained phase of vasoconstriction in rat caudal artery.	103
Figure C3.	In small mesenteric arteries combined inhibition of PKC and ROK prior to ET-1 stimulation attenuates the initiation of contraction.	106
Figure C4.	In small mesenteric arteries inhibition of PKC and ROK prior to ET-1 stimulation attenuates sustained contraction.	107
Figure C5.	During the sustained phase of ET-1-mediated contraction subsequent inhibition of PKC and ROK attenuates contraction in rat caudal artery.	109
Figure D1.	The sensitivity and maximum contractile responses to the exogenously applied thromboxane mimetic, U46619 are significantly decreased following chronic exposure to elevated ET-1.	130
Figure D2.	The contractile response to ET-1 receptor activation is unchanged following chronic exposure to elevated ET-1.	132
Figure D3.	The contractile response to α_1 -adrenergic receptor activation is not statistically different following chronic exposure to elevated ET-1.	134
Figure D4.	The contractile response to serotonin receptor activation is not significantly different following chronic exposure to elevated ET-1.	135
Figure D5.	Rats chronically treated with elevated ET-1 have similar maximum contractile responses to KCl-mediated depolarisation.	137
Figure D6.	eNOS abundance and activation state is similar in rats chronically treated with ET-1.	139
Figure D7.	Myosin phosphatase abundance and activation state is not significantly different in rats chronically treated with ET-1.	141
Table E1.	Clinical information for PAD and non-PAD patients	161
Table E2.	In-patient medication on day of surgery	162
Figure E1.	Figure E1. Patients with and without PAD had similar high K^+ -mediated vasoconstriction.	164

Figure E2.	The maximum subcutaneous arterial contractile response to serotonin receptor activation is higher in PAD vs non-PAD patients.	166
Figure E3.	The maximum subcutaneous arterial contractile response to α_1 -adrenergic receptor activation is higher in PAD vs non-PAD patients.	168
Figure E4.	Patients with and without PAD have similar contractile responses to thromboxane A_2 receptor activation.	170
Figure E5.	The sensitivity and maximum contractile responses to ET-1 receptor activation is similar between patients with and without PAD.	172
Figure E6.	Subcutaneous arteries from PAD and non-PAD patients have similar total eNOS and Ser1177 phosphorylation of eNOS.	175
Figure E7.	Acetylcholine-mediated vasodilation was not significantly different in 300-400 μ M subcutaneous arteries from PAD and non-PAD patients.	176
Figure E8.	Basal abundance and Thr855 MYPT-dependent activation state of myosin phosphatase is similar in patients with and without PAD.	178
Figure E9.	Patients suffering with PAD have more 5HT $_{2A}$ receptors in their subcutaneous arteries than non-PAD patients.	180

List of common abbreviations

5HT	5,hydroxytryptamine / serotonin
ABI	ankle brachial index
ADMA	asymmetric dimethylarginine
ADP	adenosine diphosphate
ANOVA	analysis of variance
APS	ammonium persulfate
ARB	angiotensin II receptor blocker
ATP	adenosine triphosphate
BH ₄	tetrahydrobiopterin
cGMP	cyclic guanosine monophosphate
COX	cyclooxygenase
CRP	c-reactive protein
CSFP	coronary slow flow phenomenon
CT	computer tomography
DAG	diacylglycerol
DFP	diisopropylfluorophosphate
DTT	dithiothreitol
EC	effective concentration
ECL	enhanced chemiluminescent
EDHF	endothelial-derived hyperpolarising factor
EDIN	epidermal cell differentiation inhibitor
eNOS	endothelial nitric oxide synthase
ET-1	endothelin-1
GDI	guanine nucleotide dissociation inhibitor
GDP	guanosine diphosphate
GEF	guanine-nucleotide exchange factors
GF109203X	bisindolylmaleimide
GTP	guanosine triphosphate
HRP	horse radish peroxidase
IgG	immunoglobulin G
ILK	integrin-linked kinase
IMA	Internal mammary artery
iNOS	inducible nitric oxide synthase
IP ₃	inositol triphosphate
L ₀	optimum resting length
LAD	left anterior descending coronary artery
LC ₂₀	20kDa regulatory light chains of myosin
L-NAME	N ^g -nitro-L-arginine methyl ester
MLCK	myosin light chain kinase
MYPT	myosin phosphatase targeting subunit
NO	nitric oxide
nNOS	neuronal nitric oxide synthase
PAD	peripheral artery disease
PDBu	phorbol 12,13-dibutyrate
PDE	phosphodiesterase
PE	phenylephrine
PGI ₂	prostacyclin

PI3K	phosphatidylinositol 3-kinase
PIP ₂	phosphatidylinositol 4,5-biphosphate
PKA	protein kinase A
PKB	protein kinase B
PKC	protein kinase C
PKG	protein kinase G
ROK	Rho-associated kinase
SAH	subarachnoid haemorrhage
SDS-PAGE	sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SR	sarcoplasmic reticulum
SSRIs	selective serotonin re-uptake inhibitors
TBS-T	Tris buffered saline – Tween 20
TCA	trichloroacetic acid
TEMED	N,N,N',N'-tetramethylethylenediamine
TPI	toe pressure index
ZIPK	zipper interacting protein kinase

Thesis Abstract

Peripheral artery disease (PAD) affects 20% of people over the age of 65 years and the prevalence increases with age. Predominately affecting the lower limbs, PAD causes chronic ischaemic leg pain, reduced quality of life, and increased risk of death by heart attack and stroke. It is well established vascular disease is a large vessel, atherothrombotic disorder, however the importance of vasospasm and/or increased vascular tone is less well recognized, particularly in the microvasculature. Current vasodilatory medical therapies have focused on extracellular Ca^{2+} entry or specific receptor blockade. Targeting subcellular enzymes to attenuate general agonist-mediated vasoconstriction has not yet been implemented. Although specific agonists, such as endothelin-1 (ET-1), have been implicated in PAD, whether chronic exposure to these vasoconstrictors causes altered receptor profiles of circulating hormones have not been identified. The direct contractile responses of diseased human microvessels to specific agonists also remain unclear.

We used 1) a rat model to identify the acute temporal activation of PKC and ROK during rapid and sustained ET-1-mediated vasoconstriction 2) a rat model of chronically elevated ET-1-mediated vasoconstriction to identify altered receptor profiles to specific agonists and 3) human subcutaneous arteries from patients with PAD to identify their functional and biochemical properties compared to age-matched non-PAD patients.

We report that PKC and ROK inhibition in large caudal and small mesenteric rat arteries are effective in attenuating acute ET-1-mediated vasoconstriction in

both the rapid and sustained phases of constriction. Chronically elevated ET-1 in a healthy rat model blunts the acute contractile response to the thromboxane A₂ mimetic, U46619 but does not change the vascular response to exogenously added ET-1, the α_1 -adrenergic agonist, phenylephrine and serotonin receptor activation. In human subcutaneous arteries we identified an increased maximum contractile response to serotonergic and α_1 -adrenergic receptor activation in PAD vs non-PAD patients, while vascular responses to K⁺-mediated activation of voltage-gated Ca²⁺ channels, thromboxane A₂, and ET-1 receptor activation were unchanged. Altered vascular reactivity was independent from the abundance and Ser1177-dependent and Thr855-dependent activation state of eNOS and myosin phosphatase, respectively. We identified, patients with PAD have more 5HT_{2A} receptors than patients with no symptomatic PAD, suggesting a possible mechanism for increased contractile responses to serotonin receptor activation.

These data suggest 1) subcellular targets that block the inhibition of myosin phosphatase may be valuable in attenuating the vasoconstrictor response to several agonists, and provide additional benefit to specific receptor blockade, 2) while elevated ET-1 is a strong marker of vascular disease, it may have less direct impact on vascular reactivity, 3) decreased contractile responses to thromboxane A₂ following chronic ET-1 infusion is most likely caused by down regulation of thromboxane A₂ receptors, which could have important implications for patients on antiplatelet agents, 4) blockade of enhanced serotonin and α_1 -adrenergic vasoconstriction may be beneficial in improving subcutaneous microvascular blood flow in patients with PAD